Fig 1A confirms these results and implies that 10.83 FPKM is the determining CPT1A expression level that produces significant differences in survival rate. Although previous studies have concluded that overexpression of CPT1A leads to poor breast cancer prognosis, to our knowledge no study has defined the deciding expression level: the expression level in which levels above or below it are predicted to result in significant differences in survival. This evidence concerns the gene CPT1A and breast carcinoma.